A Pilot/Feasibility Study of Ledipasvir/Sofosbuvir as Treatment for Hepatitis C in Hematopoietic Cell Transplantation (HCT) Recipients.
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 07 Sep 2018
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 28 Aug 2018 Status changed from recruiting to withdrawn prior to enrolment as the trial was unable to find eligible patients with untreated hepatitis C virus.
- 14 Sep 2017 New trial record